BTBP(SH:600161)2016-10-28 16:00Financial Performance - Operating revenue for the first nine months was CNY 1,350,608,496.14, representing an increase of 8.15% year-on-year[7] - Net profit attributable to shareholders of the listed company was CNY 183,896,406.12, a significant increase of 356.68% compared to the same period last year[7] - Basic and diluted earnings per share were both CNY 0.36, reflecting a growth of 356.68% year-on-year[9] - The company's net profit for the reporting period reached RMB 215,224,233.75, an increase of 74.12% compared to RMB 123,610,218.98 in the same period last year[18] - Operating profit increased by 41.82% to RMB 258,142,227.23, driven by higher revenue from blood products[17] - The total profit amounted to RMB 272,732,566.79, reflecting a 45.99% increase from the previous year[18] - Total revenue for the first nine months reached ¥1,350,608,496.14, an increase of 8.15% compared to ¥1,248,850,802.92 in the same period last year[33] - Operating profit for the first nine months was ¥258,142,227.23, up 42.0% from ¥182,022,403.16 year-on-year[34] - Net profit attributable to the parent company for the first nine months was ¥183,896,406.12, compared to ¥40,267,684.19 in the previous year, reflecting a significant increase[34] Assets and Liabilities - Total assets at the end of the reporting period reached CNY 5,822,506,822.57, an increase of 3.38% compared to the end of the previous year[7] - The total assets as of September 30, 2016, amounted to ¥5,822,506,822.57, an increase from ¥5,631,926,425.14 in the previous year[26] - The total liabilities increased to ¥3,460,634,410.49 from ¥3,395,686,836.10, reflecting a rise in both current and non-current liabilities[26] - The company's equity attributable to shareholders rose to ¥2,125,478,445.31, compared to ¥1,941,582,039.19 in the previous year[27] - Current liabilities increased to ¥1,193,356,433.16, compared to ¥1,146,697,441.96 at the beginning of the year, indicating a rise of 4.1%[31] Cash Flow - Net cash flow from operating activities for the first nine months was CNY 84,565,058.89, a decrease of 72.99% compared to the same period last year[7] - The net cash flow from operating activities for the year-to-date is ¥84,565,058.89, a decrease of ¥228,499,099.54 or -72.99% compared to the same period last year, primarily due to reduced cash receipts from vaccine sales[19] - The net cash flow from financing activities increased to ¥85,178,100.32, a significant improvement of ¥569,390,584.64 or 117.59% year-over-year, mainly due to a reduction in project loan repayments[19] - The net cash flow from financing activities for the first nine months was ¥92,040,003.03, compared to a negative cash flow of -¥331,428,115.64 in the previous year[45] - The total cash outflow for operating activities in the first nine months was ¥450,616,322.09, an increase from ¥368,892,663.98 year-over-year[44] Shareholder Information - The number of shareholders at the end of the reporting period was 25,240[12] - The largest shareholder, China Biotechnology Co., Ltd., held 53.30% of the shares, totaling 274,725,000 shares[12] - The number of shares held by the top ten unrestricted shareholders includes 274,725,000 shares held by China Biotechnology Co., Ltd.[14] - The company experienced a decrease in minority shareholders' profit by 62.41%, primarily due to a significant drop in the net profit of its subsidiary[18] Operational Developments - The company is actively working on integrating its blood product business under a single platform, with plans to transfer relevant assets to Tian Tan Biological Products[19] - The establishment of a wholly-owned subsidiary, Beisheng Research Company, has been approved, with asset transfers currently in progress[20] - The company has committed to eliminating competition between its subsidiaries and Tian Tan Biological Products by March 15, 2018, to enhance operational compliance and protect minority investors[19] Inventory and Receivables - Accounts receivable rose by 88.76% to RMB 282,546,970.69, primarily due to increased operating income[16] - The company's prepayments surged by 245.52% to RMB 28,408,647.21, attributed to increased advance payments for materials[16] - Other receivables increased by 199.89% to RMB 55,088,790.06, mainly due to receivables from special reserve funds[16] - The inventory value reached ¥1,086,397,659.75, compared to ¥944,348,079.31 in the previous year, indicating an increase in stock levels[25] Expenses - The company reported a significant decrease in other business costs, down 57.98% to RMB 3,910,871.34, due to a decline in semi-finished product sales[17] - Sales expenses for Q3 2016 were CNY 9,222,217.14, an increase from CNY 7,531,441.22 in Q3 2015[37] - Management expenses for Q3 2016 were CNY 71,124,939.94, compared to CNY 39,179,691.35 in the same period last year[37] - Financial expenses for Q3 2016 were CNY 22,098,605.14, down from CNY 26,875,748.04 in Q3 2015[37]